Now Reading: Alembic Pharma gets USFDA nod for generic ear infection drug
-
01
Alembic Pharma gets USFDA nod for generic ear infection drug
The Story in Brief
Alembic Pharmaceuticals Ltd announced on Monday (19 October 2026) that it has received final USFDA approval for its generic Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3%/0.1%. The drug is therapeutically equivalent to Sandoz Inc's Ciprodex Otic Suspension and is indicated for certain ear infections in patients aged six months and older, including paediatric, adult and elderly patients.
According to IQVIA data cited by Alembic, the US market for this product was estimated at USD 110 million for the 12 months ending June 2026. With this clearance, Alembic has accumulated 246 ANDA approvals from the US health regulator, 226 final and 20 tentative.
Indian Opinion Analysis
Both Business Standard and Medical Dialogues report the same facts from Alembic Pharma's press release: final USFDA approval for its generic Ciprofloxacin and Dexamethasone Otic Suspension, the drug's indications, the USD 110 million market size, and a cumulative 246 ANDA approvals. The coverage is uniform straight reporting, neither outlet adds independent comment, regulatory risk, or competitive context. Both lead with the approval itself and end with the cumulative tally. The only meaningful difference is length: Business Standard runs the press release nearly verbatim, while Medical Dialogues slightly shortens the clinical detail. Neither outlet lists a next step such as a launch date or a financial target. The key point left open is whether Alembic will commence commercial shipments immediately or face any market challenges.
Coverage: 2 sources, 2 neutral
Sources (2): business-standard.com (neutral report), medicaldialogues.in (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
